Given the relationship between non-alcoholic fatty liver disease and liver cancer, it is interesting to speculate that via this S1P/SREBP mechanism, caspase-2 could ultimately be potentiating the risk of liver cancer. Here, CASP2 is linked to metabolic dysfunction-associated steatotic liver disease.